Subject Index

AND gate in calcium homeostasis, 7
Aβ. *See* β-amyloid
AβP (1-40) channels
  cation-selective, 258-260
  conductance of, 260-261
Afterhyperpolarization, Ca^{2+}-dependent K^+-mediated, 354
Afterpolarization, calcium-dependent, 394
Agatoxins, 267
Age and membrane cholesterol content, 130
Aging
  and calpains, 79-80
  and nimodipine, 431-448
  brain, 1-9
    calcium antagonists in, 467-472
  calcium channel blockers in, 125-137, 431-448
  calcium hypothesis of, 452
  calcium rationale in, 382-402
  calcium-activated neutral proteinase in, 77-87
  changes in calcium currents and homeostasis in, 365-378
  hippocampal calcium channel activity in, 351-361
  normal, and Alzheimer's disease, line between, 396-399
  normal, cellular mechanisms of, and calcium, 390
Agonist-operated calcium channels (AOCCs), calcium influx via, 141
AIDS dementia and NMDA antagonists, 218-219
AIDS, neuronal loss in central nervous system in, 206
AIDS-related dementia and calcium homeostasis, 205-220
Allocortices, involvement of, in Alzheimer's disease, 16, 17
Alpha 1 subunit of neuronal calcium channels, 283
Alpha 2 subunit of neuronal calcium channels, 286
Alzheimer's disease, 183, 190-191
  and memory loss, 245-253
  apoptosis in, 36-47
  biosynthesis in brain in, 113
  bombesin and K^+ channel function in, 250
  calcium and neuronal injury in, 50-67
  calcium hypothesis of, 1-9
  calcium rationale in, 382-402
  calcium-activated neutral proteinase in, 77-87
  cellular changes in, 12-30
  cultured fibroblasts in diagnosis of, 225-228
  1,4-DHP calcium channel blockers in, 125-137
  excitotoxic neuronal injury in, 162
  intracellular calcium release in, 248-249
  lobular changes in, 13-15
  magnetic resonance spectroscopy in, 111-118
  metabolic changes in, 110-121
  neural membrane cholesterol composition in, 111-118
  neuroanatomical changes in, 12-30
  neuronal cytoskeletal proteins in, 92-103
  neuronal death in, and amyloid β-protein, 256-263
  nimodipine in, 336
  phospholipids in brain in, 113
  potassium channel function in, 246
Amlodipine. *See* Calcium channel blockers
  in examining membrane lipids in AD and aging, 132-135
Amyloid β-protein [AβP (1-40)] in neuronal death in AD, 256-263
Amyloid precursor protein in aging and Alzheimer's disease, 225
Amyotrophic lateral sclerosis (ALS), 274
  excitotoxicity in, 183-184
Antioxidants in preventing β-amyloid aggregation, 64
AOCCs. *See* Agonist-operated calcium channels
ApoE as susceptibility gene in Alzheimer's disease, 5
Apoptosis. *See also* Programmed neuronal death
  in Alzheimer's disease, 36-47
Arachidonic acid in HIV, 210
Association cortices in Alzheimer's disease, 18-19, 21
Associative memory, acquisition and storage of, 245
Astrocytes and HIV-related neuronal damage, 213
Autoimmunity involving calcium channels, 183-191

β subunit calcium channels, 296
β-amyloid
  in apoptosis in Alzheimer's disease, 36-37
  in Alzheimer's disease, 85-86

in K^+ channel dysfunction, 249-250
precursor protein in Alzheimer's disease, 50-67
βA4 peptides, 338
βA4 protein, 341
βAPP. *See* β-Amyloid precursor protein
Bay K 8644, 341
neuronal effects of, 272
Bcl-2, role of, in neuronal survival, 172-173
Behavior, aging, and nimodipine, 437-439
Biosynthesis in Alzheimer's disease brain, 113
Blebs in apoptosis, 39
Bombesin and IP^3 generation in AD fibroblasts, 248
Brain
aging of, 1-9
calcium antagonists in, 467-472
autopsied, in Alzheimer's disease and aging, 226
hippocampal neurons in, confocal imaging of, 315-318
hippocampal region of, patch clamping of, 315-337
in Alzheimer's disease, 113-114
learning-induced cellular changes in, 245
Lewy bodies in, 101
paired helical filaments τ (PHFτ) in, 97-98
Brodmann's area. *See* Perirhinal cortex

C-*fos* in cell death, 175-177
C-*jun* in cell death, 175-177
C-*myc* in cell death, 175
CA1 hippocampal neurons, 354
Caffeine-induced $[Ca^{2+}]_{in}$ transients in neurons, 375
$[Ca^{2+}]_i$ homeostasis
in Alzheimer's disease, 50, 248
loss of, in Alzheimer's disease, 50
$[Ca^{2+}]_i$. *See* Cytosolic calcium concentration
Calbindin-D28d protein, 437
Calcium, 1-9
and cell death, 140-155
and excitotoxic neuronal injury, 162-167
and neuronal injury in Alzheimer's disease, 50-67
bombesin in release of, 248
in Aβ-mediated apoptosis, 41-46
in aging and Alzheimer's disease, 77-87, 351-361
influx
depolarization-induced, 247
ligand-gated, 320
voltage-gated, 319-320
intracellular, blocks programmed neuronal death, 195-202
pumps, 378
rationale in aging and Alzheimer's disease, 382-402
regulation of, in aging neurons, 407-416
release, 320-321
thapsigargin in, 249
resting free, in neurons, 367
Calcium antagonists
clinical applications of, 400-401
in aging brain, 467-472
in central nervous system, 271
Calcium binding proteins
aging, and nimodipine, 437
in Alzheimer's disease, 190-191
in amyotrophic lateral sclerosis (ALS), 190
in Parkinson's disease, 190-191
Calcium channel antagonists. *See also* Magnesium, Nimodipine
in apoptosis, 46
Calcium channel blockers
in Alzheimer's disease, 66
in aging, 431-448
and Alzheimer's disease, 125-137
Calcium channels
activity in aging and dementia, 351-361
α_1 subunits, 294
and amyloid β-protein, 256-263
autoimmunity involving, 183-191
β subunits, 295
neuronal, 282-291
voltage-dependent, in cultured neurons, 325-332
voltage-gated, 294-300
pharmacology of, 267-275
Calcium currents
in aged brain neurons, 354
in mammalian neurons, 365-378
neuronal, 372
Calcium exchangers, 378
Calcium homeostasis, 341, 348, 351, 378
abnormal, in Alzheimer's disease, 228
and AIDS-related dementia, 205-220
disruption of, by β-amyloid in AD, 59-61
Calcium hypothesis
of Alzheimer's disease and brain aging, 1-9
of brain aging, 452
Calcium imaging in hippocampal neurons, 313-323
Calcium set-point hypothesis of neuronal survival, 198-201
Calcium transients, 291
depolarization-induced, 367-368
measurement of, in brain slices, 318
Calcium-dependent membrane currents in senescent fibroblasts, 302

Calcium-mediated processes in neuronal degeneration, 140-155
Calmodulin in calcium survival, 201
Calpain I in aging and Alzheimer's disease, 81-83
Calpain II and neurofibrillary pathology, 84-85
Calpains in aging and Alzheimer's disease, 77-87
Calpastatin, 83
  in modulating calpain activity, 78
cAMP, reduced formation of, in Alzheimer's disease, 232
Cardiolipin in AD brain, 115
Cataract formation, 80
Ced genes in cell death programs, 173-174
Cell calcium metabolism, 141-146
Cell damage, calcium-related, 146-155
Cell death
  in Alzheimer's disease, 5
  programmed, 195-202
  transcription factors in, 172-178
Cell dysfunction in Alzheimer's disease, 5
Cells, cultured, in Alzheimer's disease, 226
Cellular changes in Alzheimer's disease, 12-30
Cerebral microvascular pathology in Alzheimer's disease, 9
Cholesterol in membrane in Alzheimer's disease and aging, 126
Chromosome 21, mapping of gene for βAPP to, 57
Class A calcium channels, 294-300
CLSM. *See* Confocal laser scanning microscopy
Condensed nuclear chromatin in apoptosis, 39-41
Conditioned eyeblink, 338-339
Confocal laser scanning microscopy, 313-323
  to measure $[Ca^{2+}]_i$, 338
Conotoxins, 267
COOH-terminal sequences, 282
Cortical pathology in Alzheimer's disease, 22-28
Cyclic AMP and calcium currents, 373
Cysteine proteinases. *See* Calpains
Cytoskeletal proteins, 87
  abnormal, in Alzheimer's disease, 3
Cytoskeleton, influence of calcium on, 50
Cytosolic calcium concentration in Alzheimer's disease, 1-9

Degenerative disease. *See* Alzheimer's disease, Cataract formation, Wallerian degeneration, Huntington's disease
Dementia, 1-9. *See also* Alzheimer's disease, Lewy body dementias
  AIDS-related, and calcium homeostasis, 205-220
  hippocampal calcium channel activity in, 351-361
Dentate gyrus, hippocampal, 452-463
Depolarization, 325, 348
  and calcium transients, 367-368
  chronic, in neuronal survival, 196
  in assessing potassium channel function, 247
  prolonged, and L-type calcium channel, 205
DHP. *See* Dihydropyridines
Diagnostic tests in AD, usefulness of fibroblasts in, 237
Differential phosphorylation of calcium channel subunits, 285
Differential splicing, 285
Dihydropyridines
  and calcium channel activity, 358-359
  in AD, 125-137
DNA fragmentation in apoptosis, 39
Dorsal root ganglion neurons, 366
  calcium channel currents in, 326-328
Down's syndrome, altered processing of βAPP in, 57
DRG. *See* Dorsal root ganglion

Electrophysiologic studies of hippocampus, 351-352
Endoplasmic reticulum and caffeine, 375
Endstage Alzheimer's disease, 21
Entorhinal cortex, changes in, in Alzheimer's disease, 15, 20, 23, 28
Environmental excitotoxin in pathogenesis of AD, 55
Enzymes, alterations in, in Alzheimer's disease, 119-120
Excitatory amino acids, 205. *See also* Glutamate
Excitotoxic neuronal injury and calcium, 162-167
Excitotoxicity
  calcium in, 41
  glucocorticoids and glutamate in, 53

Fas/APO-1 antigen in cell death, 174
Fibroblasts
  in pathophysiology and diagnosis of AD, 225-238
  senescent human, 302-310
Fluorescence studies of brain tissue in Alzheimer's disease, 119
Free radical metabolism and altered βAPP metabolism, 64

Fura-2, 366
  imaging in evaluating role of calcium in apoptosis, 43
  to measure $[Ca^{2+}]_i$, 337-338

G-proteins
  altered coupling of, to receptors in AD, 232-233
  and ion channels, 326, 328
  binding of, by βAPP, 58
Gene factors in Alzheimer's disease, 5
Genes, novel, in senescent human fibroblasts, 302-310
Glucocorticoids and calcium currents in hippocampal neurons, 359
Glucose metabolism in Alzheimer's disease, 9
Glutamate
  depolarization induced by, 367-368
  in controlling neuronal calcium levels, 205
  in synaptic transmission, 51-53
  metabotropic, and calcium release, 321
  neurotoxicity, induction of, 163-166
gp120-induced neuronal injury in HIV, 206, 209

Heterogeneity of Alzheimer's disease, 3
Hippocampal dentate gyrus, 437-438
Hippocampus
  confocal imaging of, 314
  glutamatergic transmission and, 51
HIV envelope protein, 207
HIV. *See* Human immunodeficiency virus
HIV-1 proteins in neuronal injury, 213
HIV-related neuronal injury, 210
Homeostasis
  calcium, 351, 431
    in mammalian neurons, 365-378
  of $[Ca^{2+}]_i$ in Alzheimer's disease, 248
Human immunodeficiency virus (HIV), 206
Huntington's disease, 83
Hypertension
  and nimodipine in aging, 441-442
  pathogenesis of, calcium in, 447

Interleukin-1β (IL-1β) in HIV, 210
Ion transport systems and calcium in aging neurons, 407-416
IP^3 generation and bombesin in Alzheimer's disease fibroblasts, 248

Kinases. *See* Protein kinase C

L-type calcium channels, 273, 282, 325, 351, 395, 440-441
  nimodipine and, 338
Lambert-Eaton syndrome, 274
Learning, calcium and cellular mechanisms of, 388-390
Learning deficits, aging-associated, 386-388
Learning-induced cellular changes in brain, 245
Lewy bodies in brain, 101
Lewy body dementias, neuronal cytoskeletal proteins in, 92-103
Lewy body disease, 98-99
Ligand-gated calcium influx, 320
Limbic lobe, changes in, in Alzheimer's disease, 15, 19-21
Lipid composition of neural membranes in AD, 127
Lobular changes in Alzheimer's disease, 13-15
Long-term potentiation, synaptic modifications induced by, 460
LTP. *See* Long-term potentiation

Macrophage/microglial lineage, 206-208
Magnesium, 393
  and calcium channels, 353
  ion concentration and calcium channels, 328-332
^{31}P Magnetic resonance spectroscopy in Alzheimer's disease, 111-118
MAP kinase phorphorylates tau in neurofibrillary tangles, 53-55
Memantine, 217
Membrane currents in human diploid fibroblasts, 305
Membrane lipids, x-ray diffraction to examine, 125, 128-129
Membrane-associated metabolic changes in Alzheimer's disease, 110-121
Memory and Alzheimer's disease, 245-253
Metabolism
  membrane-associated changes in, in AD, 110-121
  of cell calcium, 141-146
Microscopy
  confocal, calcium imaging using, 313-323
  video imaging, 366
Microvascular morphology, aging, and nimodipine, 434-435
Mitochondria in Alzheimer's disease brain, 115
Modular distribution of cortex in Alzheimer's disease, 24-28
Molecular mechanisms of memory in AD, 256-263
Molecular pharmacology of voltage-gated calcium channels, 267-275
Monoglyceride lipase in Alzheimer's disease brain, 120
Morris water maze, 339

Motoneurons, calcium current in, and ALS IgG, 188-189
Muscarinic acetylcholine receptors in synaptic transmission, 51

N-type calcium channels, 282, 325
Na^+/Ca^{2+} exchanger activity in synaptic membranes, 413
Neuroanatomical changes in Alzheimer's disease, 12-30
Neurodegeneration and calpains, 80-81
Neurodegenerative disease. *See* Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Parkinson's disease
Neurofibrillary tangles, 53
  in Alzheimer's disease, 84, 92
Neuronal calcium channels, effect of ALS IgG on, 187-188
Neuronal changes, β-amyloid in, in Alzheimer's disease, 37-38
Neuronal cytoskeletal proteins
  in Alzheimer's disease, 92-103
  in Lewy body dementias, 92-103
Neuronal death
  in Alzheimer's disease, amyloid β-protein in, 256-263
  programmed, and elevated calcium, 195-202
Neuronal degeneration, calcium-mediated processes in, 140-155
Neuronal growth cone, regulation of, by $[Ca^{2+}]_i$, 50
Neuronal injury
  and calcium in Alzheimer's disease, 50-67
  excitotoxic, and calcium, 162-167
Neuronal loss in central nervous system in AIDS patients, 206
Neuronal plasticity, 275
Neurons
  aging, ion transport and calcium regulation in, 407-416
  calcium homeostasis in, 365-378
  calcium-mediated processes in, 385-386
  cultured, voltage-dependent calcium channels in, 325-332
  dorsal root ganglion, calcium channel currents in, 326
  hippocampal, 352, 354
    calcium imaging in, 313-323
Neuropharmacology of nimodipine, 336-349
Neuroprotection, nimodipine-induced, 349
Neurotoxicity, calcium, 351
Neurotrophic factors
  effect of calcium on, 50
  in protecting neurons from insult, 61
Nimodipine, 207, 392, 394-395
  in aging brain, 467-472
  in aging normotensive rats, 432-448
  neuropharmacology of, 336-349
Nitric oxide synthase, 207
Nitroglycerin, 218
Nitrosonium ion equivalents, 218
NMDA open-channel blockers, 216-217
NMDA receptors
  and HIV-related neuronal injury, 215
  in gp120-induced neuronal injury, 208-209

Oxidative deficits in AD tissues, 233-235

P-type calcium channel, 282, 295
p53 in cell death, 175
Paired helical filaments (PHF) in neurofibrillary tangles, 94
Paired helical filaments tau (PHFτ) in brain, 97-98
Parkinson's disease, 127, 183, 190-191
  Lewy bodies in, 99-100
Patch clamping
  in studying calcium currents, 366
  of hippocampal region of brain, 315, 337
  whole-cell, 305-306
Peptide toxin. *See* ω-Agatoxin, ω-Conotoxin
Periallocortical involvement in Alzheimer's disease, 16, 17
Perirhinal cortex, involvement of, in Alzheimer's disease, 20, 23, 28
Peroxynitrite, 218
PHF. *See* Paired helical filaments
Phosphatidylcholine (PTDc) in AD brain, 115
Phosphatidylinositol cascade, abnormal, in Alzheimer's disease, 231
Phosphatidylinositol kinase in AD brain, 120
Phosphodiesters (PDE)
  in AD brain, 115, 120
  in aging, 111
Phospholipase C in Alzheimer's disease, 119
Phospholipase D in AD brain, 120
Phospholipids. *See also* Cardiolipin, Phosphatidylcholine, Phosphatidylinositol kinase, Phospholipase C, Phospholipase D, Monoglyceride lipase
  in Alzheimer's disease brain, 113
    at autopsy, 115-117
Phosphomonoesters (PME), levels of, in aging, 111-112
Phosphorylation, differential, of calcium channel α_1 subunits, 285
Plasma membrane calcium transport mechanisms, 409-412
Platelet-activating factor (PAF) in HIV, 210
Posttranslational proteolytic processing, 285

Potassium channels
altered, in Alzheimer's disease, 230
dysfunction of, β-amyloid in, 249-250
function of, in Alzheimer's disease, 246
Potassium, elevated, programmed cell death blocked by, 196-198
Programmed cell death. *See* Apoptosis.
Programmed neuronal death, intracellular calcium blocks, 195-202
Proisocortex of limbic lobe, involvement of, in AD, 19
Protease inhibitor. *See* Calpastatin
Protein kinases and calcium channel phosphorylation, 285
Proteins. *See also* Amyloid β-protein, Neuronal cytoskeletal proteins
altered processing of, in AD, 235-237
PTX substrate G-proteins and ion channels, 326

Quinolinate, 214

Receptor internalization, 275
Redox modulatory site on NMDA receptor, 217
RU 28362, 359

Senescence, fibroblast, calcium-dependent membrane currents in, 302
Senile plaques in Alzheimer's disease, 92, 112
Signal transduction in Alzheimer's disease, 225, 228, 235
Single channel conductance, 372
Sporadic neurodegenerative disease, 184
Stroke
hippocampal alterations, and behavioral dysfunction, 443
hypertension, and nimodipine in aging, 441-442
Synaptic changes after long-term potentiation induction, 459
Synaptic contacts, morphological classification of, 453-454
Synaptic plasma membrane Na^+/Ca^{2+} exchanger, 413-415
Synaptic plasticity, 352-353
and long-term potentiation, 454-459
Synaptic ultrastructure, aging, and nimodipine, 436-437
Synaptosomal calcium regulation in aging neurons, 412-413
Synaptosomes, 413

T-type channels, 325
Tau. *See also* Neuronal cytoskeletal proteins
Tau protein in aging and Alzheimer's disease, 225
Thapsigargin in calcium release, 200, 249
Toxins in Alzheimer's disease, 9
Transcription factors in cell death, 172-178
Tromethamine blocks AβP (1-40) channels, 257-258
Tumor necrosis factor receptor type 1 (TNF-R1) in cell death, 174
Tumor necrosis factor-alpha (TNF-α) in HIV, 210
Tyrosine phosphorylation, stimulation of, 66

VACC. *See* Voltage-activated calcium channels
VDCC. *See* Voltage-dependent calcium channels
VGCC. *See* Voltage-gated calcium channels
Voltage-activated calcium channels, 351-352
Voltage-dependent calcium channels in cultured neurons, 325-332
Voltage-gated calcium channels, 294-300
and calpain, 80-81
in amyotrophic lateral sclerosis, 285
pharmacology of, 267-275
Voltage-gated calcium influx, 319-320
Voltage-sensitive calcium channels (VSCCs), calcium influx via, 141
VSC 4.1 cells and ALS IgG, 188
VSCCs. See Voltage-sensitive calcium channels

W-Agatoxin IVA, 297, 325-326
ω-Conotoxin GVIA, 325-326
Wallerian degeneration, 80
WS3-10 mRNA in senescent fibroblasts, 303
WS3-10 novel gene sequence, 304-305

Index of Contributors

Alexianu, M., 183-194
Alkon, D. L., 225-244, 245-255
Anderson, A. J., 36-49
Appel, S. H., 183-194
Arispe, N., 256-266

Beermann, M., 77-91
Berrow, N., 325-335
Blass, J., 225-244
Brown, T. H., 313-324

Campbell, V., 325-335
Catterall, W. A., 282-293
Chisholm, J., 336-350
Choi, D. W., 162-171
Colom, L., 183-194
Cotman, C. W., 36-49
Curran, T., 172-182

De Jong, G. I., 431-451
DeToledo-Morrell, L., 452-466
Disterhoft, J. F., ix, 382-406
Dolphin, A. C., 325-335

Elliott, E. M., 282-293
Engelhardt, J., 183-194
Etcheberrigaray, R., 225-244, 245-255

Fanelli, R. J., 336-350
Franklin, J. L., 195-204

Gandy, S., 225-244
Geinisman, Y., 452-466
Gibson, G., 225-244, 245-255
Gispen, W. H., ix, 419-430
Goldstein, S., 302-312
Griffin, W. R., 77-91
Grynspan, F., 77-91

Hamers, F. P. T., 419-430
Hell, J. W., 282-293
Honda, T., 77-91
Huang, H.-M., 225-244
Huang, M., 302-312

Ito, E., 225-244

Jaffe, D. B., 313-324
Johnson, E. M., Jr., 195-204

Kanfer, J. N., 110-124
Katayama, S., 77-91
Khachaturian, Z. S., ix, 1-11
Kirischuk, S., 365-381
Klunk, W. E., 110-124
Kostyuk, P., 365-381

Landfield, P. W., 351-364
Lee, V. M.-Y., 92-109
Lipschitz, D., 302-312
Lipton, S. A., 205-224
Liu, S., 302-312
Loo, D. T., 36-49
Luiten, P. G. M., 431-451
Lumpkin, C. K., Jr., 302-312

Martins, R., 225-244
Mason, R. P., 125-139
Mattson, M. P., 50-76
McCarthy, R. T., 336-350
McClure, R. J., 110-124
Menon-Johansson, A. M., 325-335
Michaelis, M. L., 407-418
Mohan, P. S., 77-91
Morell, F., 452-466
Morgan, J. I., 172-182
Mosier, D., 183-194
Moyer, J. R., Jr., 382-406

Nixon, R. A., 77-91

Panchalingam, K., 110-124
Pearson, H. A., 325-335
Pettegrew, J. W., 110-124
Pollard, H. B., 256-266
Pronchuk, N., 365-381

Rojas, E., 256-266

Saito, K.-I., 77-91
Sather, W. A., 294-301
Schuurman, T., 431-451, 467-474
Shea, T. B., 77-91
Shmigol, A., 365-381
Siesjö, B. K., 140-161
Smith, R. G., 183-194
Soares, H. D., 172-182
Solodkin, A., 12-35
Stefani, E., 183-194

Tanabe, T., 294-301
Thompson, L. T., 382-406
Thweatt, R., 302-312
Traber, J., ix, 467-474
Triggle, D. J., 267-281
Trojanowski, J. Q., 92-109

Tsien, R. W., 294-301

Van Hoesen, G. W., 12-35
Verkhratsky, A., 365-381

Watt, J. A., 36-49

Westenbroek, R. E., 282-293
Whittemore, E. R., 36-49

Zhang, J.-F., 294-301